SCHEMBL14015271

SCHEMBL14015271

CC(C)(C)Cc1cccc(S(=O)(=O)Nc2ccccc2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.63
POLB P06746 1/20 0.59
PGR P06401 4/20 0.55
KEAP1 Q14145 2/20 0.54
IL1RN P18510 1/20 0.54
ERAP1 Q9NZ08 1/20 0.54
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
PKM P14618 1/20 0.51
KMT2A Q03164 1/20 0.51
CA12 O43570 2/20 0.51
CA9 Q16790 2/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
HDAC2 Q92769 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
IKBKB O14920 1/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1691398 0.91 HTR6 (0.67) HTR6POLBKEAP1IL1RNERAP1
SCHEMBL23554973 0.83 GHSR (0.64) HTR6KEAP1IL1RNERAP1MEN1
SCHEMBL1696862 0.83 HTR6 (0.68) HTR6POLBPGRKEAP1IL1RN
SCHEMBL14015272 0.82 KEAP1 (0.63) KEAP1ALDH1A1PKMCA12CA9
SCHEMBL10213284 0.81 LMNA (0.45) HTR6MEN1ALDH1A1KMT2AGAA
SCHEMBL4064536 0.80 HTR6 (0.68) HTR6POLBPGRKEAP1IL1RN
SCHEMBL23306394 0.80 HTR6 (0.68) HTR6POLBPGRKEAP1IL1RN
SCHEMBL1692226 0.79 HTR6 (0.63) HTR6POLBPGRKEAP1IL1RN
SCHEMBL13865093 0.79 ALDH1A1 (0.49) KEAP1MEN1ALDH1A1KMT2ACA9
SCHEMBL8081768 0.79 KEAP1 (0.79) HTR6POLBPGRKEAP1IL1RN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7453002-B2 thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-18 US disclosed
US-7453002-B2 thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-18 US disclosed